Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLC
BMI was not an independent predictor of survival outcomes in advanced NSCLC treated with ICI. Incorporating BMI with other patient-specific factors into personalized immunotherapy strategies highlights the importance of tailored approaches to improve patient care and clinical outcomes.
Authors
- Olivia Dan
- Alexander Yakobson
- Ashraf Abu Jama
- Ahron Yehonatan Cohen
- Itamar Gothelf
- Yulia Dudnik
- Abed Agbarya (ORCID: https://orcid.org/0000-0002-3330-2959)
- Amichay Meirovitz (ORCID: https://orcid.org/0000-0001-7479-2926)
- Walid Shalata (ORCID: https://orcid.org/0000-0002-7570-4550)
- Sondos Shalata
- Lena Tourkey
- Tom Liba
Institutions
- Ben-Gurion University of the Negev (IL)
- Bar-Ilan University (IL)
- Western Galilee Hospital (IL)
- Soroka Medical Center (IL)
- Bnai Zion Medical Center (IL)
Publication Details
- Journal
- Cancers
- Published
- 2025-03-29
- DOI
- https://doi.org/10.3390/cancers17071149
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05